Last reviewed · How we verify
Sofosbuvir and Daclatasvir for 24 weeks
Sofosbuvir inhibits hepatitis C virus (HCV) NS5B RNA polymerase while daclatasvir inhibits NS5A protein, together blocking viral replication.
Sofosbuvir inhibits hepatitis C virus (HCV) NS5B RNA polymerase while daclatasvir inhibits NS5A protein, together blocking viral replication. Used for Chronic hepatitis C virus (HCV) infection, treatment-naïve and treatment-experienced patients.
At a glance
| Generic name | Sofosbuvir and Daclatasvir for 24 weeks |
|---|---|
| Sponsor | ANRS, Emerging Infectious Diseases |
| Drug class | Direct-acting antiviral (DAA) combination |
| Target | HCV NS5B RNA polymerase and HCV NS5A protein |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Sofosbuvir is a nucleotide analog that acts as a chain terminator of HCV RNA synthesis by inhibiting the NS5B polymerase. Daclatasvir is a non-structural protein 5A (NS5A) inhibitor that disrupts viral replication and assembly. Together, this combination directly targets two essential HCV enzymes, providing potent antiviral activity across multiple HCV genotypes.
Approved indications
- Chronic hepatitis C virus (HCV) infection, treatment-naïve and treatment-experienced patients
Common side effects
- Fatigue
- Headache
- Nausea
- Diarrhea
Key clinical trials
- Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs
- DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C) (PHASE4)
- Re-treatment of HCV Following DAA Failure (NA)
- Hepatitis C Treatment Study in Myanmar
- Metabolic Changes in Chronic HCV Patients Receiving DAAS
- Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir (PHASE4)
- Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model (NA)
- Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: